London: GSK plc has announced that the European Medicines Agency (EMA) has accepted the company's regulatory application to ...

EMA accepts for regulatory review GSK’s RSV vaccine, Arexvy to expand use in adults 18 years and older: London, UK Saturday, June 14, 2025, 10:00 Hrs [IST] GSK plc announced tha ...

In other developments, the ECDC today reported a slow rise in COVID activity in the Europe, which may partly reflect waning ...

The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease ...

GSK (LSE:GSK) announced that the European Medicines Agency accepted its regulatory application to expand the use of its RSV ...

GSK has applied to the European Medicines Agency to expand use of its respiratory syncytial virus (RSV) vaccine to adults ...

The panel meeting for Moderna's RSV shot, scheduled for later this month, will be the "first time for investors to see the ...

Pfizer's RSV shot Abrysvo was cleared by the FDA last October for the 18 to 59 age group, extending its 2023 approval in the ...

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

LONDON, UK I June 13, 2025 I GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted the company’s regulatory ...

Arexvy was the first RSV vaccine approved in the European Economic Area for the prevention of lower respiratory tract disease caused by RSV in adults aged 60 and older, and for those aged 50 to 59 ...

The IDF said the attack was in response to the Iranian regime's ongoing aggression against Israel. Dozens of jets struck military targets in various locations of Iran in a first stage, the IDF said.